How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics
Preview text: How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics View in…
No image available for this email.
- Subject
- How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics
- Preview text
- How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics View in…
- From
- services@
staccc.com - ESP
- Mailchimp
- Sent
- Wed Jul 29, 2026, 3:59 PM ET
- Size
- 47 KB
- Images
- 10
- Links
- 16, 3 of them buttons
- Subject length
- 77 characters
Against Rakovina Therapeutics's usual
Sent in the 3 PM hour, which holds 13% of its emails; 31% arrive in the 4 PM hour. The subject is 77 characters; its average is 70.
Email headers
What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.
- From
- Rakovina <[email protected]>
- Reply-To
- Rakovina <[email protected]>
- Subject
- How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics
- Date
- Wed, 29 Jul 2026 19:59:17 +0000
- Message-ID domain
- mail201.suw12.mcsv.net
- Return-Path domain
- mail201.suw12.mcsv.net
- DKIM signature
- d=mailchimpapp.net s=k3
- List-Unsubscribe
- Present, one-click
- Mailer
- Mailchimp Mailer
- Feedback-ID sender
- mc
Servers it passed through, newest first
- from mail201.suw12.mcsv.net [198.2.190.201] by our receiving server with ESMTPS
- from localhost [127.0.0.1] by mail201.suw12.mcsv.net with ESMTP
Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype
Sent just before and after
| Aug 31, 2026 7:00 PM | Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update | |
| Aug 31, 2026 4:42 PM | Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement | |
| Aug 19, 2026 7:01 AM | Rakovina Therapeutics Announces Results from 2026 Annual General Meeting | |
| Aug 12, 2026 4:30 AM | Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement | |
| Aug 2, 2026 4:01 PM | New AI Collaboration: Expanding Drug Discovery with Variational AI's Enki™ Platform | |
| Jul 29, 2026 3:59 PM | How AI is Revolutionizing DDR-Based Cancer Therapies at Rakovina Therapeutics (this email) | |
| Jul 26, 2026 3:57 PM | Thank You for Signing Up! |
More from Rakovina Therapeutics
All Rakovina Therapeutics emailsAnnouncing our partnership with Artemis AI
Nov 10, 2026 12:27 PM
Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
Nov 4, 2026 10:45 AM
AI narrows the focus for our brain-targeted cancer drug
Oct 30, 2026 11:32 AM
kt-5000AI update: what we’ve shown, and what’s next
Oct 22, 2026 4:17 PM
Rakovina secures exclusivity on kt-5000 target profile
Oct 18, 2026 4:14 PM · Resent
Rakovina secures exclusivity on kt-5000 target profile
Oct 15, 2026 10:30 AM
Rakovina partners with Celvion: what it means for our ATR program
Oct 1, 2026 4:18 PM
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
Sep 17, 2026 4:45 AM







